II. Indications
- Peptic Ulcer Disease
- Gastroesophageal Reflux
- Erosive Esophagitis
- Zollinger-Ellison Syndrome
III. Contraindications
- Hypersensitivity to Proton Pump Inhibitors
- Use with caution in severe liver disease
IV. Dosing: Adult
- See Helicobacter Pylori Treatment
- Background
-
Duodenal Ulcer or erosive Esophagitis
- Take 40 mg orally daily
- Zollinger Ellison Syndrome
- Take 40 mg orally twice daily OR
- Administer 80 mg IV every 8 to 12 hours until taking oral medications
V. Dosing: Child
- Indicated in GERD with erosive eosphagitis
- Weight <15 kg (off-label)
- Give 0.5 to 1 mg/kg/day
- Weight 15 to 40 kg
- Give 20 mg orally daily for up to 8 weeks
- Weight >=40 kg
- Give 40 mg orally daily for up to 8 weeks
VI. Pharmacokinetics
- All PPIs have short plasma half life of 1-2 hours
- Effect is delayed 5-7 days until proton pumps are fully blocked
- Metabolized by CYP2C19
VII. Mechanism
VIII. Adverse Effects:
IX. Precautions
X. Safety
- Pregnancy Category B
- Unknown safety in Lactation
XI. Efficacy
XII. Drug Interactions
XIII. Resources
- Pantoprazole (DailyMed)
XIV. References
Images: Related links to external sites (from Bing)
Related Studies
pantoprazole (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
PANTOPRAZOLE 40 MG SUSPENSION | Generic | $9.18 each |
PANTOPRAZOLE DR 40 MG SUSP PKT | Generic | $10.58 each |
PANTOPRAZOLE SOD DR 20 MG TAB | Generic | $0.05 each |
PANTOPRAZOLE SOD DR 40 MG TAB | Generic | $0.06 each |
protonix (on 1/1/2023 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
PROTONIX 40 MG SUSPENSION | Generic | $11.98 each |
PROTONIX DR 40 MG TABLET | Generic | $0.06 each |
Ontology: pantoprazole (C0081876)
Definition (NCI) | A substituted benzimidazole and proton pump inhibitor with antacid activity. Pantoprazole is a lipophilic weak base that crosses the parietal cell membrane and enters the acidic parietal cell canaliculus where it becomes protonated, producing the active metabolite sulphenamide, which forms an irreversible covalent bond with two sites of the H+/K+-ATPase enzyme located on the gastric parietal cell, thereby inhibiting both basal and stimulated gastric acid production. |
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C064276 |
SnomedCT | 317317009, 395821003 |
LNC | LP171628-3 |
English | 1H-Benzimidazole, 5-(difluoromethoxy)-2-(((3,4-dimethoxy-2-pyridinyl)methyl)sulfinyl)-, pantoprazole, pantoprazole (medication), pantoprazole [Chemical/Ingredient], PANTOPRAZOLE, Pantoprazole, Pantoprazole (product), Pantoprazole (substance) |
Spanish | pantoprazol (producto), pantoprazol (sustancia), pantoprazol |
Ontology: Protonix (C0876139)
Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
MSH | C064276 |
English | Protonix, pantoprazole (Protonix), protonix |